Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service vitreoretinal surgery cases in Iowa: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 13 | 756 | 24% |
| 2020 | 12 | 782 | 27% |
| 2021 | 14 | 883 | 30% |
Pars plana vitrectomy and retinal detachment repair. Professional codes (what the surgeon bills): CPT 67036, 67040, 67041, 67042, 67108, 67113.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 90% of the cases CMS names in Iowa; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cataract & MIGS | 68 | 18,172−5.5%/yr | −5.5%/yr | 40.40.6× | 61% | 20,600 in 2030+2.1%/yr |
Vitreoretinal surgery in every state, and its device makers · Every procedure market in Iowa · Every state · Compare with Ohio
| 2024 |
| 772 |
| 40% |
| 2025 est. | ≈ 780 | – |
| 2026 est. | ≈ 810 | – |
| 2022 | 15 | 822 | 34% |
| 2023 | 18 | 812 | 38% |
| 2024 | 14 | 772 | 40% |
| 2025 from claims | – | 783 633–919 | 41% |
| 2026 forecast | – | 814 637–1,022 | 40% |
| 2027 forecast | – | 829 615–1,096 | 40% |
| 2028 forecast | – | 845 598–1,167 | 41% |
| 2029 forecast | – | 862 586–1,235 | 41% |
| 2030 forecast | – | 878 575–1,303 | 42% |
In 2025, 33% hospital outpatient, 67% surgery center. The share outside the hospital has moved −11 pts since 2019.
| −5.7%/yr |
| 2.0 |
| 42% |
| 2,740 in 20300%/yr |
| Missouri | 35 | 1,908−0.3%/yr | −0.3%/yr | 3.1 | 51% | 1,740 in 2030−1.5%/yr |
| Michigan | 23 | 1,526−8.8%/yr | −8.8%/yr | 1.8 | 29% | 1,320 in 2030−2.3%/yr |
| Indiana | 24 | 1,476−4.2%/yr | −4.2%/yr | 2.1 | 74% | 1,530 in 2030+0.6%/yr |
| Wisconsin | 18 | 1,472−1%/yr | −1%/yr | 2.6 | 29% | 1,730 in 2030+2.7%/yr |
| Minnesota | 21 | 1,192−4.8%/yr | −4.8%/yr | 2.7 | 73% | 1,540 in 2030+4.3%/yr |
| Kansas | 18 | 1,141−5.2%/yr | −5.2%/yr | 2.8 | 60% | 1,150 in 2030+0.2%/yr |
| Nebraska | 9 | 735−1.3%/yr | −1.3%/yr | 2.8 | 72% | 740 in 20300%/yr |
| South Dakota | 7 | 578+4.1%/yr | +4.1%/yr | 4.5 | 100% | 1,010 in 2030+9.8%/yr |
| North Dakota | 2 | 184+6.1%/yr | +6.1%/yr | 1.9 | 73% | 130 in 2030−5.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Alcon leads with 76% of company spending on these surgeons in 2025, +34 pts on 2024.
In 2025, 11 companies reported engagement with Iowa’s surgeons worth $53K in consulting, speaking, meals and travel tied to these products, about $3,783 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 0 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.